Sample Digests

See what a curated research digest looks like. Real papers from top journals, structured summaries, tailored to specific research interests.

Sample Digest · Sample Digest

Solid Tumor Immunotherapy

checkpoint inhibitorsPD-1 blockadeCAR-T cellstumor microenvironmentneoadjuvant immunotherapy
1
EliteNew England Journal of Medicine

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

Cercek A, Lumish M, Sinopoli J, et al.

Key Findings

  • All 12 patients (100%) with mismatch repair–deficient locally advanced rectal cancer achieved complete clinical response to dostarlimab monotherapy
  • At median follow-up of 12 months, no patient had received chemoradiotherapy or undergone surgery
  • No adverse events of grade 3 or higher were reported during the treatment period

Why This Matters

A landmark result suggesting that a subset of rectal cancer patients may avoid surgery, radiation, and chemotherapy entirely through immunotherapy alone — directly relevant to anyone tracking checkpoint inhibitor response in solid tumors.

2
EliteNew England Journal of Medicine

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Forde PM, Spicer J, Lu S, et al.

Key Findings

  • CheckMate 816: neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved event-free survival vs chemotherapy alone in resectable NSCLC (HR 0.63; P=0.005)
  • Pathological complete response rate: 24.0% in the nivolumab-chemo arm versus 2.2% with chemotherapy alone
  • Safety profile consistent with known profiles of the individual components; no new signals observed

Why This Matters

Establishes neoadjuvant immunotherapy as a new standard-of-care option in resectable lung cancer, shifting the treatment paradigm from post-surgical to pre-surgical checkpoint blockade.

3
EliteNew England Journal of Medicine

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Munshi NC, Anderson LD Jr, Shah N, et al.

Key Findings

  • KarMMa trial: anti-BCMA CAR-T therapy (ide-cel) achieved 73% overall response rate in heavily pretreated relapsed/refractory multiple myeloma
  • Complete response rate of 33% at the target dose level; median progression-free survival of 8.8 months
  • Cytokine release syndrome occurred in 84% of patients (grade 1–2 in most cases); neurotoxicity in 18%

This is a sample of 3 papers. A typical Tailored digest includes 10 papers per project (up to 40 total across 4 projects).

290+

Peer-reviewed journals and preprint servers tracked weekly

100,000+

Papers processed by our selection algorithm each week

5 min

Average time to scan your weekly digest over morning coffee

Get your own personalized digest

Define your research interests. Our advanced selection algorithm delivers the papers that matter to you, every Monday morning.